Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 2:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 208 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Methotrexate placebo Clear all
Completed Phase 2 Interventional Results available

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

NCT01164579
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

NCT00458146
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MM-093
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
20
States / cities
Montgomery, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Sep 8, 2026, 2:31 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
144
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT00106535
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
61
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

Effects of Abatacept in Patients With Early Rheumatoid Arthritis

NCT02504268
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Abatacept Placebo, Methotrexate Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
42
States / cities
Huntsville, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 1 Interventional

Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout

NCT06186219
View directory record Official record
Conditions
Tophaceous Gout
Interventions
Rituximab
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

NCT00520572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD9056, Etanercept, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 8, 2026, 2:31 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Voraxaze for Delayed Methotrexate Clearance

NCT00424645
View directory record Official record
Conditions
Hematologic Malignancy, Solid Tumor
Interventions
Voraxaze (Glucarpidase), Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 3 Interventional

Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis

NCT00036153
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tacrolimus (Prograf®), Methotrexate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

NCT00195702
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 1Phase 2 Interventional

Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis

NCT00959036
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
ATN-103, Placebo, Methotrexate
Drug
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

NCT01645280
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

NCT00689728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY2127399, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Birmingham, Alabama • Mesa, Arizona • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

NCT00928512
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Secukinmab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Mesa, Arizona • Peoria, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study

NCT02576067
View directory record Official record
Conditions
Vascular Inflammation, Atherosclerotic Cardiovascular Disease
Interventions
Low dose methotrexate, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 8, 2026, 2:31 PM EDT
Terminated Phase 2 Interventional Results available

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

NCT02862574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Andecaliximab, Placebo, Methotrexate, TNF Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00718718
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg, Placebo, Methotrexate
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Aventura, Florida • Lexington, Kentucky • Frederick, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 4 Interventional Results available

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

NCT00420927
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
adalimumab, methotrexate, placebo
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

NCT00853385
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo, Biologic TNFi
Drug · Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
38
States / cities
Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

NCT04247815
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ATI-450, Placebo oral tablet, Methotrexate
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Anniston, Alabama • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Inflammation Reduction Trial

NCT01594333
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Methotrexate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4,786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
404
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 296 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 2 Interventional

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

NCT01008852
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
SBI-087, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
20
States / cities
Paradise Valley, Arizona • Palm Desert, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 1 Interventional Results available

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

NCT00847886
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LX3305, LX3305 Placebo, Methotrexate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Sep 8, 2026, 2:31 PM EDT
Completed Phase 2 Interventional Results available

Abatacept With Methotrexate- Phase IIB

NCT00162266
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (BMS-188667), Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 8, 2026, 2:31 PM EDT